Category Archives: Biotechnology

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning

The continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment.

To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

iland haveworked with many companies in the healthcare, life sciences and biotech industries. Therefore, it knowsfrom experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world.

>See also:10 trends that will influence cloud computing in 2017

For example, ilandrecently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the cloud. As a result, itsDR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three additional key benefits that cloud brings to biotech organisations.

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade.

These days, thanks largely to cloud technology, it can be done in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning.

Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing black box that obscures details needed to accurately interpret the results of computational analyses.

>See also:How cloud computing can transform the pharmaceutical industry

In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications.

Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily. For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed.

At the same time bio-technologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible it centralises data, ensuring security and data sovereignty while facilitating collaboration.

It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues.

Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

>See also:Managed cloud: making the most out of public cloud computing

As well as enhanced billing visibility and resource management functions, the release of the vendors secure cloud services means that the itscloud now includes on-demand security and compliance reports.

This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future. From research and development to marketing, computing affects everything an organisation does.

Sourced by Monica Brink, director of marketing, iland

More here:
Exploring the cloud laboratory: biotechnology and cloud computing - Information Age

Puma Biotechnology Inc (NYSE:PBYI) daily sentiment score is -0.018 for articles printed on 2017-03-18. This is on a -1-1 scale after assessing the buzzing news and its impact on the system. The assessment is hooked on the dependable web sources.

Bullish target is at $89 while conservative price target is $72 on respective equity.

Puma Biotechnology Inc has an ABR of 1.67. The stock rating was 1.67 in preceding quarter. Financial numbers can be released on 2017-05-09. Consensus estimated EPS is $-1.88 for this quarter.

Securities prices are motivated by fundamentals in both the controlled and open street. Informed or not, shareholders weightage is on fiscals and other allied valuation basics. The metrics under contemplation are per-share earnings and associated ratios. Investors shift their emphasis on comprehensive financial report. Also, they predict miscellaneous components, which consists the reserves and other firm resources and also its valuation to due debt. Definitely, it is an unusual exercise to assess and measure all features while generating funds in equity market. A disciplined appraisal bodes well when the notion is to contribute a fair part in planned income.

Whatever ratings Zacks gives can to some degree exhibit variance from calls of First Call. Both the entities dont poll same set of street analysts, and as a result the projections vary. Puma Biotechnology Inc (NYSE:PBYI) posted EPS of $-2.04 for period closed on 2016-12-31. The reported number was $-0.02 off from the consensus. In percentage terms variance was -0.99%.

More here:
Puma Biotechnology Inc (NYSE:PBYI) Impact Score At 0 - Stock Observer

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a daily volume of 1.19 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $35.79, and its 200-day SMA $42.49. Puma Biotechnology Inc has a P/B ratio of 7.77.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Headquartered in Los Angeles, CA, Puma Biotechnology Inc has 160 employees and is currently under the leadership of CEO Alan H. Auerbach.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

View original post here:
Puma Biotechnology Inc (PBYI) Moves Higher on Volume Spike for March 17 - Equities.com

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

See more here:
NAS Issues Report on Preparing for Future Products of Biotechnology - JD Supra (press release)

The Cerbat Gem

Analysts Set Puma Biotechnology Inc (PBYI) Price Target at $70.50 The Cerbat Gem Shares of Puma Biotechnology Inc (NYSE:PBYI) have earned an average recommendation of Hold from the eight ratings firms that are presently covering the ... Traders Recap: Puma Biotechnology Inc (NASDAQ:PBYI ...NYSE Journal (press release) Puma Biotechnology Inc (NASDAQ:PBYI) Reviewed By Analysts ...The De Soto Edge all 5 news articles »

Read the original here:
Analysts Set Puma Biotechnology Inc (PBYI) Price Target at $70.50 - The Cerbat Gem

Triad Business Journal

College hires leader for Biotechnology Center of Excellence Triad Business Journal Our Biotechnology Center of Excellence will be key to Alamance County's economic development and we are excited to have an administrator with the depth and breadth of experience as Yonnie Butler, said President Algie Gatewood. His range of ...

Link:
College hires leader for Biotechnology Center of Excellence - Triad Business Journal

Ceramist Susan Beiners work has been exhibited in China, France, the Netherlands and across the nation, but it took some persuading to get her to exhibit her creations at Temple Solels latest Art Showcase.

After some cajoling, Beiner relented and now her earlier work is on display at Temple Solel through May 31. A reception and talk featuring Beiner are scheduled for 10:30 a.m. Sunday, April 2, at Temple Solel, 6805 E. McDonald Drive, Paradise Valley.

Your current subscription does not provide access to this content. Please click the button below to manage your account.

kAmp %6>A=6 $@=6= >6>36C D:?46 a_`b[ q6:?6C 😀 2? 2DD@4:2E6 AC@76DD@C 2E pC:K@?2 $E2E6 &?:G6CD:EJD[ w6C36C86C r@==686 @7 u:?6 pCE] w6C 96D:E2?4J E@ D9@H 96C H@C< 2E $@=6= 42>6 7C@> E96 724ED E92E D96 925 ?6G6C 4@?D:56C65 5:DA=2J:?8 96C 2CE 😕 2 DJ?28@8F6 367@C6[ 2D H6== 2D E96 =2C86 D:K6 @7 96C =2E6DE 4C62E:@?D]k^Am

kAm(6 E@=5 $FD2? D96 H2D 2 EC6>6?5@FD C6D@FC46 2?5 2 A2CE @7 E96 E6>A=6 2?5 H6 H2?E65 E@ D66 96C H@C<[ D2:5 xC2 %9@>2D[ 2 >6>36C @7 E96 pCE o $@=6= 4@>>:EE66] %9:D 😀 E96 7:CDE E:>6 H6G6 925 2 46C2>:4:DE]k^Am

kAmx?DA:C65 3J E96 4C27ED >@G6>6?E[ q6:?6C 3682? 4C62E:?8 9:89=J 56E2:=65[ 2?5 2E E:>6D H9:>D:42=[ E62A@ED 😕 E96 62C=J `hh_D] p=E9@F89 D96 DE:== E@@< AC:56 :? 96C E62A@ED[ 3J a__b[ q6:?6C D2:5 D96 ?66565 2 8C62E6C 2CE:DE:4 492==6?86 2?5 >@G65 @? E@ =2C86 H2== :?DE2==2E:@?D 2?5 D4F=AEFC6D]k^Am

kAmx ;FDE 5:5?E H2?E E@ >2<6 E62A@ED 2?J>@C6[ q6:?6C D2:5] x 5:5?E 766= 2D E9@F89 E96 E62A@ED H6C6 23@FE E96 7F?4E:@?2= AC@5F4E 😕 2?J H2J] x E9:?< E96J H6C6 >@C6 23@FE 2 7@C> H:E9 H9:49 E@ >2<6 >@C6 D4F=AEFC2= @C:6?E2E:@?] p7E6C x 5:5 >J 7:CDE =2C86 H2== A:646 😕 a__b[ x 76=E x 4@F=5 8@ 7FCE96C] x 4@?D:56C E96 E62A@ED 😕 2 5:776C6?E H2J E92? x 5@ >J =2E6DE H@C<] ,%96 ?6H H@C<. :D 2 5:776C6?E >:?5D6E @7 9@H x> >2<:?8 :E[ H9J x> >2<:?8 :E 2?5 E96 :562D 369:?5 :E]k^Am

kAm%96 E9:?8D x >2<6 ?@H E2<6 2 =@E =@?86C[ 3FE E96J 2C6 >@C6 @7 2 492==6?86 2?5 x E9:?< E96J 86E 36EE6C 2?5 36EE6C H:E9 E:>6[ q6:?6C 25565] x =62C? 7C@> 6249 @?6 2?5 E@ >6 E92E 😀 H@CE9 6G6CJE9:?8]k^Am

kAm{:<6 96C E62A@ED[ 96C ?6H H@C2E6C:2=D DF49 2D A=6I:8=2DD[ 7@2> 2?5 24CJ=:4D] uC@> 272C[ E96 C6DF=ED 42? =@@< =:<6 2 82C56? @7 7=@H6CD F?E:= 4=@D6C 6I2>:?2E:@? C6G62=D E96 >2?>256[ :?5FDEC:2= 2CE:7:46 E92E C6AC6D6?ED 96C :?E6C6DE 😕 ?2EFC6 2?5 3:@E649?@=@8J]k^Am

kAm*@F 42?E E6== H92ED C62= 2?5 H92ED >256 2?J>@C6[ q6:?6C D2:5] (6 42? 8C@H 2?JE9:?8 😕 E6C>D @7 v|~D W86?6E:42==J >@5:7:65 @C82?:D>DX 2?5 E9:?8D =:<6 E92E] *@F 42? 8C@H 2?J A=2?E E@ 36 D@>6E9:?8 6=D6] %96C6 2C6 2== D@CED @7 E9:?8D E92E 2C6 36:?8 5@?6 E92E >2<6 >J H@C< D66> >@C6 C62=]k^Am

kAmsF6 E@ DA246 =:>:E2E:@?D 2E %6>A=6 $@=6=[ q6:?6C 😀 >@DE=J 6I9:3:E:?8 96C 62C=J E62A@ED]k^Am

kAmq6:?6C 😀 A2CE @7 E96 E9:C5 42==E@2CE:DED 7@C E96 pCE $9@H42D6 D6C:6D 2E %6>A=6 $@=6= D:?46 a_`a] $96 😀 ;@:?65 3J D6G6? @E96C 2CE:DED H@C<:?8 :? DF49 >65:F>D 2D 24CJ=:4D[ @:=[ A9@E@8C2A9J 2?5 A2:?E:?8] %96 2CE:DED H@C< 42? 2=D@ 36 AFC492D65[ H:E9 2 A6C46?E286 @7 E96 AC@4665D 8@:?8 E@ 7F?5 2? 2CE D49@=2CD9:A 2H2C565 2??F2==J E@ 2 E6>A=6 >6>36C 9:89 D49@@= D6?:@C]k^Am

kAm(6G6 366? C62==J 3=6DD65 92G:?8 D@ >2?J %6>A=6 $@=6= >6>36CD H:E9 D@ >2?J 5:G6CD6 <:?5D @7 E2=6?ED E2=6?ED E92E D@>6 @7 E96> 5@?E 6G6? C64@8?:K6 E96>D6=G6D[ %9@>2D D2:5] |6>36CD @7 @E96C DJ?28@8F6D 92G6 G:D:E65 %6>A=6 $@=6= E@ D66 E96 G2C:@FD pCE $9@H42D6D] %9@>2D 9@A6D E92E :?E6C6DE H:== 3=@DD@> :?E@ D@>6E9:?8 3:886C]k^Am

kAm(6C6 C62==J 9@A:?8 E92E 5@H? E96 C@25 H6 42? 86E 2? 2CE 4@>>F?:EJ H:E9:? E96 #67@C> 4@?8C682E:@?D 😕 E96 '2==6J[ 96 D2:5]k^Am

Janet Perez is a freelance writer based in Phoenix.

Continued here:
Ceramics artist inspired by nature, biotechnology - Jewish News of Greater Phoenix

The Nasdaq Composite Index rose Wednesday, buoyed by broad advances at biotechnology and IT companies, after the Federal Reserve decided to raise interest rates for the second time in three meetings.

The technology-heavy index rose 0.7% to 5,900.05, its fifth advance in the last six sessions. The benchmark index settled just below all-time highs.

With the gain, the Nasdaq has returned nearly 10% for the year, outpacing the S&P 500 Index and Dow Jones Industrial Average.

A total of 2,009 companies listed on the Nasdaq reported gains, versus 888 that finished lower and 229 that went unchanged. A total of 166 companies reported new highs, versus 47 that set new lows.

Health stocks listed on the S&P 500 rose more than 1%, with pharmaceuticals, biotechnology and life sciences leading the rally. Information technology also advanced 0.6% as a sector.

Advertising

The Nasdaq Biotechnology Index rose 1.5% to 3,162.82.

The Federal Reserve raised its benchmark interest rate by a quarter point to 1% in a move that was widely anticipated by the markets. Policymakers continue to expect three rate increases this year, putting the central bank on course for two additional adjustments in 2017.

In terms of upcoming releases, the U.S. Labor Department will report on initial jobless claims on Thursday. Separately, the Commerce Department will report on housing starts and building permits. The Philadelphia Fed will also report on regional manufacturing conditions in the early morning.

Link:
Nasdaq Composite Index Approaches Record High as ... - Economic Calendar

Mar 16, 2017 (LBO) Sri Lankas cabinet has agreed to establish the Biotechnology Innovation Park in the Nanotechnology Park in Pitipana, Homagama as a public-private partnership project.

This years budget allocated 100 million rupees for the establishment of this facility which will provide facilities mainly for companies engaged in the pharmaceutical industry and genomics.

Apart from the land, the government will also allocate utilities such as electricity and water for the proposed facility.

Global market for biotechnology is estimated at over 453 billion US dollars in 2016 with an annual growth of over 10 percent.

In 2013, Sri Lankas first ever Nanotechnology and Science Park was commissioned in Homagama with the government investing over 2 billion rupees and six private companies cumulatively investing 310 million rupees.

Potential Sectors for Sri Lankan Biotechnology Industry Development

Enzyme: food, detergent, garment etc. Synthetic biology Pharmaceutical: Vaccines( including recombinant), anti-venom, antibiotics, herbal product drug delivery mechanisms etc. Medical diagnostics : Genomics, regenerative medicine etc. Tissue engineering : production of cell lines Bioinformatics Clinical trails Bioenergy Neutraceuticals and therapeutics Bio-products : bio-fertilizer, bio-pesticides etc Marine biotechnology : medicinal, food, chemical Environmental biotechnology : waste management Agriculture Biotechnology : crop improvement molecular breeding, biotech crops etc.

Read the original post:
Sri Lanka to set up Rs100mn Biotechnology Park in Homagama - Lanka Business Online

Sam Konduros(Photo: Provided)

Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization.

SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials.

Konduros is a currently a member of the SCBIO Board of Directors.

I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement.

Architecture and design firm adds new hire to Greenville office

Verizon looks to fill 100 positions at new telesales center in Greenville

Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts.

He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce.

Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. He is alsoa graduate of the Economic Development Institute at the University of Oklahoma.

Sams strengths in knowing the biotech sector and his deep experience in business and economic development were compelling, Erin Ford, chair of SCBIO, said in a statement. The board was won over by his vision for the growth of SCBIO.

Read or Share this story: http://grnol.co/2mJTIWt

The rest is here:
Sam Konduros named president and CEO of SC Biotechnology Industry Organization - Greenville News